Pacira Pharmaceuticals (NASDAQ:PCRX)‘s stock had its “hold” rating restated by stock analysts at Canaccord Genuity in a report released on Friday, February 16th. They presently have a $32.00 target price on the stock. Canaccord Genuity’s price objective points to a potential upside of 4.75% from the stock’s current price.
Several other research firms also recently weighed in on PCRX. Oppenheimer reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Thursday, February 15th. HC Wainwright reissued a “buy” rating and set a $52.00 target price on shares of Pacira Pharmaceuticals in a research report on Thursday, November 9th. Janney Montgomery Scott cut Pacira Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $27.00 price objective for the company. in a report on Thursday, October 26th. Jefferies Group dropped their price objective on Pacira Pharmaceuticals to $52.00 and set a “buy” rating for the company in a report on Thursday, November 9th. Finally, JPMorgan Chase & Co. started coverage on Pacira Pharmaceuticals in a report on Monday, December 18th. They set a “neutral” rating and a $47.00 price objective for the company. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have issued a buy rating to the stock. Pacira Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $45.29.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded down $1.30 during trading hours on Friday, reaching $30.55. The company’s stock had a trading volume of 848,498 shares, compared to its average volume of 1,120,000. Pacira Pharmaceuticals has a fifty-two week low of $29.35 and a fifty-two week high of $52.47. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.96 and a quick ratio of 6.22. The stock has a market capitalization of $1,240.00, a PE ratio of -28.03 and a beta of 1.95.
In other news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total value of $1,160,888.15. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 6.60% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of PCRX. Northern Trust Corp boosted its stake in shares of Pacira Pharmaceuticals by 9.1% in the second quarter. Northern Trust Corp now owns 505,529 shares of the company’s stock worth $24,114,000 after buying an additional 42,289 shares during the last quarter. Vanguard Group Inc. boosted its position in Pacira Pharmaceuticals by 7.4% during the second quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock worth $146,538,000 after purchasing an additional 211,982 shares in the last quarter. California Public Employees Retirement System boosted its position in Pacira Pharmaceuticals by 2.2% during the second quarter. California Public Employees Retirement System now owns 64,700 shares of the company’s stock worth $3,086,000 after purchasing an additional 1,400 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in Pacira Pharmaceuticals by 26.0% during the second quarter. Parametric Portfolio Associates LLC now owns 111,193 shares of the company’s stock worth $5,304,000 after purchasing an additional 22,949 shares in the last quarter. Finally, QS Investors LLC purchased a new position in Pacira Pharmaceuticals during the second quarter worth approximately $157,000.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.